Tempest Therapeutics, Inc. Net Fee Amt
Tempest Therapeutics, Inc. (TPST) had Net Fee Amt of $1.28 thousand as of 2026-08-21, per its S-1 filed 2026-08-21.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-21
- 2026-08-21: Net Fee Amt $1.28K.
- 2026-06-24: Net Fee Amt $415.59.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-21 | $1.28K S-1 · filed 2026-08-21 |
| 2026-06-24 | $415.59 S-3 · filed 2026-06-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |